Cilostazol—A Forgotten Antiplatelet Agent, But Does it Even Matter?∗  by Lavie, Carl J. & DiNicolantonio, James J.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 6 , N O . 9 , 2 0 1 3
ª 2 0 1 3 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 3 . 0 6 . 0 0 6EDITORIAL COMMENT
CilostazoldA Forgotten
Antiplatelet Agent,
But Does it Even Matter?*Carl J. Lavie, MD,yz James J. DiNicolantonio, PHARMDx
New Orleans, and Baton Rouge, Louisiana; and Ithaca,
New York
Cilostazol is a phosphodiesterase III inhibitor that has anti-
platelet effects due to subsequent increases in cyclic adenosine
monophosphate within platelets (1). This agent also provides
vasodilation, improves endothelial function, inhibits vascular
smooth muscle cell growth, inhibits neointimal hyperplasia,
and seems to reduce the risk of restenosis and major adverse
cardiac events (MACE) after percutaneous coronary inter-
ventions (PCI), without signiﬁcantly increasing major
hemorrhagic events, and has potential cardiovascular pro-
tection in patients with acute myocardial infarction (MI) and
acute coronary syndromes (ACS) (1–4).See page 932Dual antiplatelet therapy (DAPT) with aspirin and
a P2Y12 adenosine receptor antagonist has become the
standard of care following PCI and ACS. Typically, aspirin
has been combined with clopidogrel, but both of these agents
have substantial risk of resistance (5,6), especially in certain
populations. The Asian population and those from Korea, as
in the present study, may be particularly resistant to clopi-
dogrel’s antiplatelet effects, with a greater prevalence of high
on-treatment platelet reactivity (HOPR), which is associated
with an increased risk of MACE following PCI (7). One
potential way to overcome the HOPR with clopidogrel is to
use double-dose clopidogrel antiplatelet therapy (DDAT) in
patients undergoing PCI and those with ACS.*Editorials published in JACC: Cardiovascular Interventions reﬂect the views of the
authors and do not necessarily represent the views of JACC: Cardiovascular Interven-
tions or the American College of Cardiology.
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platelet therapy (TAPT), adding cilostazol to aspirin and
clopidogrel, which may offer advantages by reducing HOPR
in the settings of PCI and ACS without the increased risk for
a major hemorrhagic event (8,9). In particular, those with
multivessel disease, HOPR on DAPT, and others who are at
high risk of MACE or stent thrombosis show a more
favorable response when placed on TAPT as compared with
DAPT.
Several clinical trials and meta-analyses have suggested
that TAPT was superior to DAPT in patients with ACS
(10,11). In long-term studies comparing TAPT with
DAPT, TAPT had a 32% reduction in all-cause mortality
following PCI (12). Several systematic reviews and meta-
analyses have found that TAPT is more effective than
DAPT in reducing the risk of restenosis by nearly 50%, need
for recurrent revascularization by 40% to 60%, and MACE
by nearly 30%, without increasing the risk of major
hemorrhagic events (13–15).
In the present study in this issue of JACC: Cardiovascular
Interventions, Park et al. (7) assessed 1-month duration
TAPT (aspirin, clopidogrel, and cilostazol) versus DDAT
(aspirin and double-dose clopidogrel) in 3,755 patients
(two-thirds with ACS) undergoing PCI with drug-eluting
stents, and found that TAPT was noninferior to DDAT.
This study, however, was probably underpowered, as the
investigators admit, as the primary endpoint occurred in only
23 patients (1.2%) on TAPT and 27 patients (1.4%) in the
DDAT group. Despite lower HOPR with TAPT, major
bleeding was the same in both arms. Total endpoints,
including nonfatal MI (7 vs. 13), stroke (2 vs. 3), stent
thrombosis (deﬁnite or probable; 4 vs. 7), and all-cause
mortality (9 vs. 11) were all lower with TAPT. In total,
major endpoints favored TAPT versus DDAT (22 events vs.
34 events), although by our Forest plot, this was still not
statistically signiﬁcant (p ¼ 0.11), indicating the less than
ideal power of the study, thus representing the major study
limitation. Other study limitations were that more patients
on TAPT had peripheral arterial disease and more DDAT
patients had prior MI and were older. Also, allocated
therapy was given signiﬁcantly more often with TAPT, and
patients were more adherent on TAPT than DDAT. The
study also had a short follow-up (1 month), and Koreans as
a population have HOPR with the frequency of the
CYP2C19 loss of function allele being greater than 60% (7).
The strength of the study was that it was multicenter,
randomized, and blinded.
Although this study may provide some support for TAPT
being on even par versus DDAT, one could question the
clinical signiﬁcance of this ﬁnding and even ask, “Does it even
matter?” In the United States, for example, many interven-
tional cardiologists prefer the more potent available anti-
platelet therapies, such as prasugrel and ticagrelor for PCI
and ACS, and other agents (e.g., rivaroxaban) are awaiting
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944approval for ACS. Nevertheless, even if one considers these
new antiplatelet therapies superior to clopidogrel as DAPT
and even DDAT, a serious issue for many of our patients is
the cost of these newer, nongeneric, therapies. Many of our
patients currently require 10 or more prescription medica-
tions, especially in the elderly population who are prone to
increased coronary heart disease, ACS/MI, and who fre-
quently require PCI; many of the agents used to treat these
diseases are currently nongeneric. Considering cost restraints,
TAPT with aspirin, clopidogrel, and cilostazol appears to be
a viable alternative to DAPT and even DDAT. Clearly, this
therapy should be compared with DAPT with the newer
agents, as opposed to just clopidogrel, and the efﬁcacy of
TAPT should be studied with aspirin and cilostazol added to
the newer therapies to determine if further clinical efﬁcacy
can be enhanced without producing nondesirable increases in
bleeding complications.
As to whether cilostazol has a current place as a viable
antiplatelet agent and “does it even matter?,” the answer is
a resounding “maybe.” Further studies with cilostazol that
are adequately powered are needed to better determine its
viability as an adjunctive antiplatelet therapy in the current
management of ACS and PCI.Reprint requests and correspondence: Dr. Carl J. Lavie, John
Ochsner Heart and Vascular Institute, Ochsner Clinical School–The
University of Queensland School of Medicine, 1514 Jefferson
Highway, New Orleans, Louisiana 70121-2483. E-mail: clavie@
ochsner.org.
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